Evofem Biosciences Files 2024 10-K
Ticker: EVFM · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1618835
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals, financials
Related Tickers: EVFM
TL;DR
Evofem (EVFM) dropped its 2024 10-K. Financials are in. Check it out.
AI Summary
Evofem Biosciences, Inc. filed its 2024 10-K on March 24, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly known as Neothetics, Inc., is based in San Diego, California, and operates in the pharmaceutical preparations sector. The filing details its financial position and business operations, including information on various series of preferred stock and notes.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Evofem Biosciences' financial health and operational status for the past fiscal year, crucial for evaluating the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Evofem Biosciences faces inherent risks related to drug development, regulatory approvals, market competition, and financial stability, which are detailed in its 10-K filing.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-24 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Filer of the 10-K
- Neothetics, Inc. (company) — Former name of Evofem Biosciences, Inc.
- 2024-12-31 (date) — Fiscal year end date
- 2025-03-24 (date) — Filing date of the 10-K
- San Diego, CA (location) — Company headquarters location
FAQ
What was the primary business of Evofem Biosciences, Inc. during the fiscal year ending December 31, 2024?
Evofem Biosciences, Inc. operates in the Pharmaceutical Preparations [2834] sector, as indicated by its SIC code.
When did Evofem Biosciences, Inc. change its name from Neothetics, Inc.?
The date of the name change from Neothetics, Inc. to Evofem Biosciences, Inc. was September 5, 2014.
What is the SEC file number for Evofem Biosciences, Inc.'s 10-K filings?
The SEC file number for Evofem Biosciences, Inc. is 001-36754.
Where is Evofem Biosciences, Inc. headquartered?
Evofem Biosciences, Inc. is headquartered at 12400 High Bluff Drive, Suite 600, San Diego, CA 92130.
What types of preferred stock and notes are mentioned in relation to Evofem Biosciences, Inc. for the fiscal year 2024?
The filing mentions BakerBrosNotesMember, AdjuvantNotesMember, SeriesE1ConvertibleAndRedeemablePreferredStockMember, and SeriesF1ConvertibleAndRedeemablePreferredStockMember for the fiscal year 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Evofem Biosciences, Inc. (EVFM).